Cidofovir (CAS 113852-37-2) is a nucleotide analog antiviral with potent activity against human cytomegalovirus (CMV) and other DNA viruses. It is primarily indicated for the treatment of CMV retinitis in patients with AIDS, where it acts by inhibiting viral DNA polymerase after intracellular phosphorylation to its active diphosphate form.
On its dedicated product page, Cidofovir 113852-37-2 | Antiviral Nucleotide Analog API Supplier China is presented by TCS INDUSTRIES LIMITED as a specialised intravenous antiviral API for hospital and specialist settings. Thanks to its long intracellular half-life, cidofovir allows for extended dosing intervals compared with some other injectable CMV treatments, which can be advantageous in chronic management.
However, cidofovir therapy is associated with dose-dependent nephrotoxicity, requiring co-administration of probenecid and adequate hydration, along with careful renal monitoring. This risk profile means that both clinical use and manufacturing must be managed within robust risk-mitigation frameworks. TCS GROUP supports this by providing comprehensive quality documentation, impurity data and recommended storage and transport conditions to preserve potency and minimise degradation.
Formulation work with cidofovir focuses on sterile intravenous solutions. Control of pH, ionic strength and vehicle composition is essential for stability and patient tolerability. Because the product is typically used in severely immunocompromised populations, stringent microbial and particulate specifications and reliable supply are critical.
Cidofovir sits alongside other serious-disease APIs within TCS INDUSTRIES LIMITED’s Active Pharmaceutical Ingredient portfolio. For example, in oncology and high-risk patient populations, Carmustine 154-93-8 | Oncology Chemotherapy API Manufacturer China and Chlorambucil 305-03-3 provide chemotherapeutic options that may be used sequentially or concomitantly in complex treatment pathways. In ophthalmology, other agents such as Bimatoprost 155206-00-1 expand the glaucoma and vision-care portfolio for the same manufacturers.
By choosing cidofovir from TCS GROUP, partners gain a technically demanding but reliably supported antiviral API, backed by experience in potent compounds, sterile-route development and global regulatory expectations for life-saving therapies.